Keryx Biopharmaceuticals Inc (KERX)

6.52
NASDAQ : Health Care
Prev Close 6.73
Day Low/High 6.44 / 6.71
52 Wk Low/High 4.03 / 8.38
Avg Volume 1.36M
Exchange NASDAQ
Shares Outstanding 118.75M
Market Cap 799.19M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

KERX Crosses Above Average Analyst Target

In recent trading, shares of Keryx Biopharmaceuticals Inc. have crossed above the average analyst 12-month target price of $6.83, changing hands for $6.84/share.

Interesting KERX Put And Call Options For December 15th

Investors in Keryx Biopharmaceuticals Inc. saw new options begin trading this week, for the December 15th expiration.

Commit To Purchase Keryx Biopharmaceuticals At $3, Earn 20% Using Options

Investors eyeing a purchase of Keryx Biopharmaceuticals Inc. stock, but cautious about paying the going market price of $5.82/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Keryx Announces The Largest Medicare Part D Plan Sponsor Added Auryxia® To Its Medicare Part D Plan Formularies

Additional formularies expand unrestricted access to Auryxia to approximately 85 percent of phosphate binder patients across Medicare Part D and commercial insurance providers

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Shares of late-stage biopharma Cytokinetics increased following positive comments from an Needham analyst.

Keryx Biopharmaceuticals is Now Oversold (KERX)

Keryx Biopharmaceuticals is Now Oversold (KERX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of KERX February 2017 Options Trading

First Week Of KERX February 2017 Options Trading

Investors in Keryx Biopharmaceuticals Inc. saw new options become available this week, for the February 2017 expiration.

Keryx Biopharmaceuticals Announces Case Study Data Of Auryxia® Presented At ASN's Kidney Week

Keryx Biopharmaceuticals Announces Case Study Data Of Auryxia® Presented At ASN's Kidney Week

Majority of patients when started on Auryxia achieved target serum phosphorus levels within six months of treatment

January 2019 Options Now Available For Keryx Biopharmaceuticals (KERX)

January 2019 Options Now Available For Keryx Biopharmaceuticals (KERX)

Investors in Keryx Biopharmaceuticals Inc. saw new options begin trading today, for the January 2019 expiration.

Keryx Biopharmaceuticals Announces U.S. FDA Approval Of Second Contract Manufacturer For Auryxia® (ferric Citrate)

Keryx Biopharmaceuticals Announces U.S. FDA Approval Of Second Contract Manufacturer For Auryxia® (ferric Citrate)

Auryxia is now available for prescription in the U.S.